Literature DB >> 19351691

Associations of major bleeding and myocardial infarction with the incidence and timing of mortality in patients presenting with non-ST-elevation acute coronary syndromes: a risk model from the ACUITY trial.

Roxana Mehran1, Stuart J Pocock, Gregg W Stone, Tim C Clayton, George D Dangas, Frederick Feit, Steven V Manoukian, Eugenia Nikolsky, Alexandra J Lansky, Ajay Kirtane, Harvey D White, Antonio Colombo, James H Ware, Jeffrey W Moses, E Magnus Ohman.   

Abstract

AIMS: To evaluate the associations of myocardial infarction (MI) and major bleeding with 1-year mortality. Both MI and major bleeding predict 1-year mortality in patients presenting with acute coronary syndrome (ACS). However, the risk of each of these events on the magnitude and timing of mortality has not been well studied. METHODS AND
RESULTS: A multivariable Cox regression model was developed relating 13 independent baseline predictors to 1-year mortality for 13 819 patients with moderate and high-risk ACS enrolled in the Acute Catheterization and Urgent Intervention Triage strategy trial. After adjustment for baseline predictors, Cox models with major bleeding and recurrent MI as time-updated covariates estimated the effect of these events on mortality hazard over time. Within 30 days of randomization, 705 patients (5.1%) had an MI, 645 (4.7%) had a major bleed; 524 (3.8%) died within a year. The occurrence of an MI was associated with a hazard ratio of 3.1 compared with patients not yet having an MI, after adjustment for baseline predictors. However, MI within 30 days markedly increased the mortality risk for the first 2 days after the event (adjusted hazard ratio of 17.6), but this risk declined rapidly post-infarct (hazard ratio of 1.4 beyond 1 month after the MI event). In contrast, major bleeding had a prolonged association with mortality risk (hazard ratio of 3.5) which remained fairly steady over time throughout 1 year.
CONCLUSION: After accounting for baseline predictors of mortality, major bleeds and MI have similar overall strength of association with mortality in the first year after ACS. MI is correlated with a dramatic increase in short-term risk, whereas major bleeding correlates with a more prolonged mortality risk.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19351691      PMCID: PMC2695951          DOI: 10.1093/eurheartj/ehp110

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  24 in total

Review 1.  Management of acute coronary syndromes: acute coronary syndromes without persistent ST segment elevation; recommendations of the Task Force of the European Society of Cardiology.

Authors:  M E Bertrand; M L Simoons; K A Fox; L C Wallentin; C W Hamm; E McFadden; P J de Feyter; G Specchia; W Ruzyllo
Journal:  Eur Heart J       Date:  2000-09       Impact factor: 29.983

2.  Association between CK-MB elevation after percutaneous or surgical revascularization and three-year mortality.

Authors:  Sorin J Brener; Bruce W Lytle; Jakob P Schneider; Stephen G Ellis; Eric J Topol
Journal:  J Am Coll Cardiol       Date:  2002-12-04       Impact factor: 24.094

Review 3.  Nitric oxide and blood: a review.

Authors:  J P Wallis
Journal:  Transfus Med       Date:  2005-02       Impact factor: 2.019

4.  Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction.

Authors: 
Journal:  N Engl J Med       Date:  1998-05-21       Impact factor: 91.245

Review 5.  Practical problems in fitting a proportional hazards model to data with updated measurements of the covariates.

Authors:  D G Altman; B L De Stavola
Journal:  Stat Med       Date:  1994-02-28       Impact factor: 2.373

6.  ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction--summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of Patients With Unstable Angina).

Authors:  Eugene Braunwald; Elliott M Antman; John W Beasley; Robert M Califf; Melvin D Cheitlin; Judith S Hochman; Robert H Jones; Dean Kereiakes; Joel Kupersmith; Thomas N Levin; Carl J Pepine; John W Schaeffer; Earl E Smith; David E Steward; Pierre Theroux; Raymond J Gibbons; Joseph S Alpert; David P Faxon; Valentin Fuster; Gabriel Gregoratos; Loren F Hiratzka; Alice K Jacobs; Sidney C Smith
Journal:  J Am Coll Cardiol       Date:  2002-10-02       Impact factor: 24.094

7.  Acute Catheterization and Urgent Intervention Triage strategY (ACUITY) trial: study design and rationale.

Authors:  Gregg W Stone; Michel Bertrand; Antonio Colombo; George Dangas; Michael E Farkouh; Frederick Feit; Alexandra J Lansky; A Michael Lincoff; Roxana Mehran; Jeffrey W Moses; Magnus Ohman; Harvey D White
Journal:  Am Heart J       Date:  2004-11       Impact factor: 4.749

8.  Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes.

Authors: 
Journal:  N Engl J Med       Date:  1998-08-13       Impact factor: 91.245

9.  Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes.

Authors:  Sunil V Rao; James G Jollis; Robert A Harrington; Christopher B Granger; L Kristin Newby; Paul W Armstrong; David J Moliterno; Lauren Lindblad; Karen Pieper; Eric J Topol; Jonathan S Stamler; Robert M Califf
Journal:  JAMA       Date:  2004-10-06       Impact factor: 56.272

10.  Bivalirudin during primary PCI in acute myocardial infarction.

Authors:  Gregg W Stone; Bernhard Witzenbichler; Giulio Guagliumi; Jan Z Peruga; Bruce R Brodie; Dariusz Dudek; Ran Kornowski; Franz Hartmann; Bernard J Gersh; Stuart J Pocock; George Dangas; S Chiu Wong; Ajay J Kirtane; Helen Parise; Roxana Mehran
Journal:  N Engl J Med       Date:  2008-05-22       Impact factor: 91.245

View more
  57 in total

Review 1.  New anticoagulants in ischemic heart disease.

Authors:  Lawrence Rajan; David J Moliterno
Journal:  Curr Cardiol Rep       Date:  2012-08       Impact factor: 2.931

2.  Safety and tolerability of high-intensity anticoagulation with bivalirudin during neuroendovascular procedures.

Authors:  Ameer E Hassan; Muhammad Zeeshan Memon; Alexandros L Georgiadis; Gabriela Vazquez; M Fareed K Suri; Adnan I Qureshi
Journal:  Neurocrit Care       Date:  2011-08       Impact factor: 3.210

Review 3.  The impact of switching P2Y12 receptor inhibitor therapy during index hospitalization: a systematic review.

Authors:  Jaya Chandrasekhar; Benjamin Hibbert; Michael Froeschl; Derek So; Roxana Mehran; Michel Le May
Journal:  Eur J Clin Pharmacol       Date:  2015-10-09       Impact factor: 2.953

4.  Bleeding events are associated with an increase in markers of inflammation in acute coronary syndromes: an ACUITY trial substudy.

Authors:  Charles L Campbell; Steven R Steinhubl; William C Hooper; Joseph Jozic; Susan S Smyth; Debra Bernstein; Christine De Staercke; George Syros; Brian H Negus; Thomas Stuckey; Gregg W Stone; Roxana Mehran; George Dangas
Journal:  J Thromb Thrombolysis       Date:  2011-02       Impact factor: 2.300

Review 5.  Antiplatelet agents in clinical practice and their haemorrhagic risk.

Authors:  Paolo Gresele
Journal:  Blood Transfus       Date:  2013-05-09       Impact factor: 3.443

6.  Management of patients with acute coronary syndromes in real-world practice in Italy: an outcome research study focused on the use of ANTithRombotic Agents: the MANTRA registry.

Authors:  Gianni Casella; Giuseppe Di Pasquale; Luigi Oltrona Visconti; Maria Giovanna Pallotti; Donata Lucci; Pasquale Caldarola; Marino Scherillo; Aldo P Maggioni
Journal:  Eur Heart J Acute Cardiovasc Care       Date:  2013-03

7.  Welcome to the ESC journal family.

Authors:  Thomas F Lüscher
Journal:  Eur Heart J Acute Cardiovasc Care       Date:  2012-04

8.  Impact of an integrated treatment algorithm based on platelet function testing and clinical risk assessment: results of the TRIAGE Patients Undergoing Percutaneous Coronary Interventions To Improve Clinical Outcomes Through Optimal Platelet Inhibition study.

Authors:  Jaya Chandrasekhar; Usman Baber; Roxana Mehran; Melissa Aquino; Samantha Sartori; Jennifer Yu; Annapoorna Kini; Samin Sharma; Carsten Skurk; Richard A Shlofmitz; Bernhard Witzenbichler; George Dangas
Journal:  J Thromb Thrombolysis       Date:  2016-08       Impact factor: 2.300

9.  Highlights from the fifth international symposium of thrombosis and anticoagulation (ISTA V), October 18-19, 2012, Belo Horizonte, Minas Gerais, Brazil.

Authors:  Renato D Lopes; Richard C Becker; L Kristin Newby; Eric D Peterson; Elaine M Hylek; Robert Giugliano; Christopher B Granger; Kenneth W Mahaffey; Antonio C Carvalho; Otavio Berwanger; Roberto R Giraldez; Gilson Soares Feitosa-Filho; Marcia M Barbosa; Maria da Consolacao V Moreira; Renato A K Kalil; Marildes Freitas; Joao Carlos de Campos Guerra; Marcio Vinicius Lins Barros; Thiago da Rocha Rodrigues; Antonio C Lopes; David A Garcia
Journal:  J Thromb Thrombolysis       Date:  2013-07       Impact factor: 2.300

10.  Fondaparinux and acute coronary syndromes: update on the OASIS 5-6 studies.

Authors:  François Schiele
Journal:  Vasc Health Risk Manag       Date:  2010-04-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.